[Federal Register Volume 78, Number 141 (Tuesday, July 23, 2013)]
[Notices]
[Page 44136]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-17644]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB review; 30-day Comment Request: National
Cancer Institute (NCI) Cancer Nanotechnology Platform Partnership
Scientific Progress Reports
SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institutes of Health (NIH), has
submitted to the Office of Management and Budget (OMB) a request for
review and approval of the information collection listed below. This
proposed information collection was previously published in the Federal
Register on May 13, Vol. 78, p. 27974 and allowed 60-days for public
comment. No public comments were received. The purpose of this notice
is to allow an additional 30 days for public comment. The National
Cancer Institute (NCI), National Institutes of Health, may not conduct
or sponsor, and the respondent is not required to respond to, an
information collection that has been extended, revised, or implemented
on or after October 1, 1995, unless it displays a currently valid OMB
control number.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, [email protected] or by fax to 202-395-6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30-days
of the date of this publication.
For Further Information: To obtain a copy of the data collection
plans and instruments or request more information on the proposed
project contact: Dorothy Farrell, Center for Strategic Scientific
Initiatives, Office of Cancer Nanotechnology Research, National Cancer
Institute, 31 Center Drive, Bldg. 31 A, Rm. 10A52, Bethesda, MD 20892
or call non-toll-free number 301-496-5652 or Email your request,
including your address to: [email protected]. Formal requests for
additional plans and instruments must be requested in writing.
Proposed Collection: National Cancer Institute (NCI) Alliance for
Nanotechnology in Cancer Platform Partnership Scientific Progress
Reports, 0925-NEW, National Cancer Institute (NCI), National Institutes
of Health (NIH).
Need and Use of Information Collection: National Institutes of
Health grantees are required to submit interim and final progress
reports and other post-award documents associated with the monitoring,
oversight, and closeout of an award. This submission represents a
request for OMB to approve new program specific progress report
guidelines for Cancer Nanotechnology Platform Partnerships (CNPP)
awarded by the National Cancer Institute (NCI). The CNPPs are part of
the Alliance for Nanotechnology in Cancer, a network of awards funded
by NCI to promote the application of nanotechnology to cancer research
and care. The proposed guidelines request information about award
performance related to trans-Alliance collaboration, scientific
milestones, progress towards clinical translation and technology
commercialization, and education and outreach efforts. The report also
gathers information on leveraged funding, patents and publications. The
information is gathered every six months. This information is needed to
monitor the performance of this special program within NCI, funded
through Requests for Applications (RFA CA-09-013, released May 29,
2009) using the cooperative agreement mechanism (U01). The information
will be used to monitor individual award performance and the
effectiveness of the program as a whole. The respondents are the
Principal Investigators of the awards, along with their institutional
business officials. The awards are administered by and the reports
reviewed by the Office of Cancer Nanotechnology Research (OCNR), part
of the Center for Strategic Scientific Initiatives within NCI.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The estimated annualized burden
hours are 72.
Estimated Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Number of respondents responses per per response Total annual
respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Principal Investigators............. 12..................... 2 3 72
----------------------------------------------------------------------------------------------------------------
Dated: July 15, 2013.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2013-17644 Filed 7-22-13; 8:45 am]
BILLING CODE 4140-01-P